Business
Premier Biomedical Receives Notice of Allowance on Broad Base Patent Involving Innovative Extracorporeal Treatment Therapy – Premier Believes This May Lead To Cancer Cure
Premier Biomedical Receives Notice of Allowance on Broad Base Patent Involving Innovative Extracorporeal Treatment Therapy – Premier Believes This May Lead To Cancer Cure.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n \n Premier Biomedical, Inc. (OTCQB: \n BIEI) a biotech research public company focused on discovering, \n developing, and commercializing medical treatments for a wide range of \n diseases in humans, including innovative therapies for breast cancer as \n well as potential novel therapies for neurofibromatosis, atherosclerosis \n and muscular dystrophy, announced today they have obtained exclusive \n rights to the recently allowed U.S. patent application, \"Sequential \n Extracorporeal Treatment of Bodily Fluids\", covering the basic \n technology underpinning Premier's on-going research into new, innovative \n treatments for many of today's most debilitating diseases.\n \n \n Premier Biomedical, Inc. is developing a methodology for treating \n multiple diseases, such as cancer, which is completely different from \n the standard treatments now being utilized. The vast majority of \n presently known treatments directly inject possibly harmful agents into \n the body of a patient. This presents a very real risk of adverse side \n effects from the treatment.\n \n \n Premier Biomedical, Inc. intends to develop its proprietary methodology \n in which the pathologies are eradicated by sequentially dialyzing the \n patient's blood extracorporeally (outside the body). The method will \n utilize designer antibodies to physically remove the pathophysiologic \n basis of the disease. For example, in cancer treatment, there will be \n the physical attachment and removal of metastasizing cancer cells, \n proteins or molecules which are responsible for the development, \n progression and metastasis of the disease. This extracorporeal \n methodology has an enormous potential for dramatically decreasing any \n side effects in the treatment of ill patients. The estimated \n expenditures for cancer treatment in the U.S. in 2010 were approx. \n $124.5 Billion, and projected to rise to $158 - $175 Billion by 20201.\n \n \n William A. Hartman, CEO and President of Premier Biomedical, stated \n that, \"Between this sequential extracorporeal therapy patent just \n granted, and the previously granted patent Utilization of Stents for the \n Treatment of Blood Borne Carcinomas (US Patent 8,758,287: 6/24/14), I \n believe that we have a clear roadmap for potentially curing cancer, \n possibly at any stage, and even after extensive metastasis. These \n pa...